Expanded treatment in community settings will reduce patient burden Option to redose patients granted in both Ntrust-1 and Ntrust-2 studies Rheumatoid arthritis cohort to be added to Ntrust-2 Dosing ...

The patient in the current case report showed manifestations of both AAV and IgG4-RD; his improvement linked to steroid/cyclophosphamide treatment underscores the need for integrated diagnosis and ...

Adult IgA vasculitis may carry greater renal and gastrointestinal risks. Read more about diagnosis and management.

Avacopan shows a favorable safety profile in ANCA-associated vasculitis in real-world settings, with hepatobiliary events as ...

Amgen Inc. AMGN shares are down on Monday after the company announced topline results from a Phase 3 trial of TEPEZZA, which ...

Bengaluru: The U.S. Food and Drug Administration on Monday said it had identified cases of liver injury in patients taking ...

23-year-old with rare condition moves many online with selfless clean-up actions; pledges to open care home for sick and ...

A sick woman in China cleaned her own blood on a train despite her condition, and her act of responsibility moved people ...

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...

Postmarketing reports of fatal liver injury associated with avacopan have prompted the FDA to issue a safety alert and recommend new monitoring protocols.

The FDA has ramped up the pressure on Amgen to withdraw Tavneos for a rare vasculitis condition from the market, with a report saying it has identified cases of serious liver injury – including deaths ...

The FDA has issued a safety alert for Tavneos, a medication used to treat a rare autoimmune disease, due to recent reports ...